|
| 36789806 | SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy. | | 2023 |
| 35668700 | People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. | Journal of Infectious Diseases | 2023 |
| 37971267 | HIV reservoirs are dominated by genetically younger and clonally enriched proviruses. | mBio | 2023 |
| 37873490 | Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size. | | 2023 |
| 36910697 | Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. | | 2023 |
| 37090500 | HIV reservoirs are dominated by genetically younger and clonally enriched proviruses. | bioRxiv | 2023 |
| 37317505 | Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series. | | 2023 |
| 36545783 | Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. | | 2023 |
| 34888688 | Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. | Journal of Infectious Diseases | 2022 |
| 35899097 | Phylogenetic prioritization of HIV-1 transmission clusters with viral lineage-level diversification rates. | Evolution, Medicine and Public Health | 2022 |
| 36148225 | Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. | Frontiers in Immunology | 2022 |
| 36145509 | A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model. | Pharmaceutics | 2022 |
| 36331974 | HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy. | PLoS Pathogens | 2022 |
| 35543278 | Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. | Journal of Infectious Diseases | 2022 |
| 35350205 | People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses. | | 2022 |
| 36680168 | Molecular Epidemiology of HIV-1 in Ghana: Subtype Distribution, Drug Resistance and Coreceptor Usage. | | 2022 |
| 35061879 | Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. | Journal of Antimicrobial Chemotherapy | 2022 |
| 35228535 | Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. | NPJ Vaccines | 2022 |
| 35018381 | Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose. | | 2022 |
| 34473060 | Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity. | eLife | 2021 |
| 34062285 | SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. | J Mol Diagn | 2021 |
| 33791737 | Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine. | | 2021 |
| 34057182 | Corrigendum to: Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. | Journal of Infectious Diseases | 2021 |
| 33784237 | Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. | Emerging Infectious Diseases | 2021 |
| 33988715 | A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. | J Exp Med | 2021 |
| 33986282 | Author Correction: HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). | Nature Communications | 2021 |
| 33560098 | Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication. | Therapeutic Drug Monitoring | 2021 |
| 33976241 | Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs. | Scientific Reports | 2021 |
| 33420062 | HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). | Nature Communications | 2021 |
| 34578305 | Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay. | Viruses | 2021 |
| 34671779 | Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. | medRxiv | 2021 |
| 34781741 | HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. | mBio | 2021 |
| 34489909 | Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART. | Front Microbiol | 2021 |
| 34754454 | Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. | Evolution, Medicine and Public Health | 2021 |
| 32605062 | Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. | Viruses | 2020 |
| 32376625 | Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. | J Virol | 2020 |
| 32071061 | Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa. | Antimicrobial Agents and Chemotherapy | 2020 |
| 32005884 | Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. | Sci Rep | 2020 |
| 31776273 | Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4<sup>+</sup> T Cell Subsets during Long-Term Combination Antiretroviral Therapy. | J Virol | 2020 |
| 31918727 | Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study. | Retrovirology | 2020 |
| 32471096 | Are We Ready for NGS HIV Drug Resistance Testing? The Second "Winnipeg Consensus" Symposium. | Viruses | 2020 |
| 33370400 | T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics. | PLoS Pathogens | 2020 |
| 32925973 | Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. | PLoS Pathogens | 2020 |
| 33235889 | Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. | Open Forum Infectious Diseases | 2020 |
| 31546824 | Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia. | Viruses | 2019 |
| 31628022 | Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. | eBioMedicine | 2019 |
| 31554200 | Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study. | Pathogens | 2019 |
| 30602611 | HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals. | J Virol | 2019 |
| 30654177 | A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. | Infection, Genetics and Evolution | 2019 |
| 29389912 | High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia. | Viruses | 2018 |